Meeting
2013 ASCO Annual Meeting
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Authors
Erminia Massarelli
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Erminia Massarelli , Lawrence E. Ginsberg , Heather Lin , Hai T. Tran , J. Jack Lee , Michelle D. Williams , George R. Blumenschein Jr., Charles Lu , Merrill S. Kies , Vassiliki Papadimitrakopoulou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00942734
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6067)
DOI
10.1200/jco.2013.31.15_suppl.6067
Abstract #
6067
Poster Bd #
13G
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
First Author: Aarti K. Bhatia
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara
Poster
2014 ASCO Annual Meeting
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
First Author: Joel W. Neal